AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

One side of the vaccine debate is using us to score points. The other side is disregarding us entirely. Neither seems to be ...

AstraZeneca CEO Pascal Soriot unpacks President Donald Trump's drug cost cut executive order on 'The Claman Countdown.' ...

The company is searching for its next blockbuster candidate as its major revenue driver, Keytruda, is expected to lose patent ...

Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...

The benefits of 52-week biologic therapy on asthma control and lung function are observed in both never smokers and ...

CHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment ...

Multinationals on China: China has set a GDP growth target of around 5% for 2025. How do you view this target and China’s ...

Chief Executive Mark Read-who has been at the company for more than 30 years-will retire from the board and as CEO on Dec. 31. The deal for the U.K.-listed semiconductor company comes as Qualcomm ...

The iPhone maker releases live language-translation capabilities and a broad software redesign. Some AI upgrades remain delayed. Walmart-backed fintech OnePay chose Synchrony to issue the retailer's ...